Modeling compound-target interaction network of traditional chinese medicines for type II diabetes mellitus: Insight for polypharmacology and drug design

Journal of Chemical Information and Modeling

Volumn 53, Issue 7, 2013, Pages 1787-1803

  Tian, Sheng ^a   Li, Youyong ^a   Li, Dan ^b   Xu, Xiaojie ^c   Wang, Junmei ^d   Zhang, Qian ^a   Hou, Tingjun ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORECASTING; FREE RADICALS; MAPPING; MEDICINE; MOLECULAR MODELING; PHARMACODYNAMICS;

FREE RADICAL SCAVENGING; PHARMACOLOGICAL ACTIVITY; PHARMACOLOGICAL EFFECTS; PHARMACOPHORE MAPPING; PREDICTION CAPABILITY; SATISFACTORY PREDICTIONS; TRADITIONAL CHINESE MEDICINE; TYPE II DIABETES MELLITUS;

LEAD COMPOUNDS;

ANTIDIABETIC AGENT; LIGAND; PROTEIN BINDING;

BAYES THEOREM; CHINESE MEDICINE; DIABETES MELLITUS, TYPE 2; METABOLISM; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; POLYPHARMACOLOGY; ARTICLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BINDING;

BAYES THEOREM; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIC AGENTS; LIGANDS; MEDICINE, CHINESE TRADITIONAL; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; POLYPHARMACOLOGY; PROTEIN BINDING;

EID: 84880531818     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci400146u     Document Type: Article

References (93)

1. Smyth, S.; Heron, A. Diabetes and obesity: the twin epidemics Nature Med. 2006, 12, 75-80
2. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes-Estimates for the year 2000 and projections for 2030 Diabetes Care 2004, 27, 1047-1053
3. Florez, H. J.; Sanchez, A. A.; Marks, J. B. Type 2 Diabetes Diabetes and the Brain 2010, 33-53
4. Pasquier, F. Diabetes and cognitive impairment: how to evaluate the cognitive status? Diabetes Metab. 2010, 36, S100-S105
5. Reaven, G. M. Pathophysiology of insulin-resistance in human-disease Physiol. Rev. 1995, 75, 473-486
6. Ripsin, C. M.; Kang, H.; Urban, R. J. Management of Blood Glucose in Type 2 Diabetes Mellitus Am. Fam. Physician 2009, 79, 29-36
7. Morral, N. Novel targets and therapeutic strategies for type 2 diabetes Trends Endocrin. Met. 2003, 14, 169-175
8. Marcus, A. O. Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1 Diabetes Technol. Ther. 2000, 2, 101-10
9. Marcus, A. O. Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2 Diabetes Technol. Ther. 2000, 2, 275-81
10. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery Nature Chem. Biol. 2008, 4, 682-690
11. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discovery 2004, 3, 353-359
12. Hou, T.; Wang, J. Structure-ADME relationship: still a long way to go? Expert Opin. Drug Metab. Toxicol. 2008, 4, 759-770
13. Hou, T. J.; Xu, X. J. Recent development and application of virtual screening in drug discovery: An overview Curr. Pharm. Des. 2004, 10, 1011-1033
14. Winzeler, E. A.; Shoemaker, D. D.; Astromoff, A.; Liang, H.; Anderson, K.; Andre, B.; Bangham, R.; Benito, R.; Boeke, J. D.; Bussey, H.; Chu, A. M.; Connelly, C.; Davis, K.; Dietrich, F.; Dow, S. W.; El Bakkoury, M.; Foury, F.; Friend, S. H.; Gentalen, E.; Giaever, G.; Hegemann, J. H.; Jones, T.; Laub, M.; Liao, H.; Liebundguth, N.; Lockhart, D. J.; Lucau-Danila, A.; Lussier, M.; M'Rabet, N.; Menard, P.; Mittmann, M.; Pai, C.; Rebischung, C.; Revuelta, J. L.; Riles, L.; Roberts, C. J.; Ross-MacDonald, P.; Scherens, B.; Snyder, M.; Sookhai-Mahadeo, S.; Storms, R. K.; Veronneau, S.; Voet, M.; Volckaert, G.; Ward, T. R.; Wysocki, R.; Yen, G. S.; Yu, K. X.; Zimmermann, K.; Philippsen, P.; Johnston, M.; Davis, R. W. Functional characterization of the S-cerevisiae genome by gene deletion and parallel analysis Science 1999, 285, 901-906
15. Kitano, H. Towards a theory of biological robustness. Mol. Syst. Biol. 2007, 3.
16. Kitano, H. Innovation-A robustness-based approach to systems-oriented drug design Nat. Rev. Drug Discov. 2007, 6, 202-210
17. Berger, S. I.; Iyengar, R. Network analyses in systems pharmacology Bioinformatics 2009, 25, 2466-2472
18. Goh, K.-I.; Cusick, M. E.; Valle, D.; Childs, B.; Vidal, M.; Barabasi, A.-L. The human disease network Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 8685-8690
19. Yildirim, M. A.; Goh, K.-I.; Cusick, M. E.; Barabasi, A.-L.; Vidal, M. Drug-target network Nat. Biotechnol. 2007, 25, 1119-1126
20. Newman, D. J.; Cragg, G. M. Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010 J. Nat. Prod. 2012, 75, 311-335
21. Zhao, J.; Jiang, P.; Zhang, W. Molecular networks for the study of TCM Pharmacology Brief. Bioinform. 2009, 11, 417-430
22. Ji, H.-F.; Li, X.-J.; Zhang, H.-Y. Natural products and drug discovery Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 2009, 10, 194-200
23. Newman, D. J.; Cragg, G. M.; Snader, K. M. The influence of natural products upon drug discovery Nat. Prod. Rep. 2000, 17, 215-234
24. Lukman, S.; He, Y.; Hui, S.-C. Computational methods for Traditional Chinese Medicine: A survey Comput. Methods Programs Biomed. 2007, 88, 283-294
25. Chang, S.-S.; Huang, H.-J.; Chen, C.Y.-C. Two Birds with One Stone? Possible Dual-Targeting H1N1 Inhibitors from Traditional Chinese Medicine. PLoS Comput. Biol. 2011, 7.
26. Chen, K.-C.; Chang, S.-S.; Tsai, F.-J.; Chen, C.Y.-C. Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine? J. Biomol. Struct. Dyn. 2012, 1-17
27. Tou, W. I.; Chang, S.-S.; Lee, C.-C.; Chen, C.Y.-C. Drug Design for Neuropathic Pain Regulation from Traditional Chinese Medicine Sci. Rep. 2013, 3
28. Chen, K.-C.; Chang, K.-W.; Chen, H.-Y.; Chen, C.Y.-C. Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once? Mol. Biosyst. 2011, 7, 2711-2719
29. Chen, X.; Ung, C. Y.; Chen, Y. Z. Can an in silico drug-target search method be used to probe potential mechanisms of medicinal plant ingredients? Nat. Prod. Rep. 2003, 20, 432-444
30. Ehrman, T. M.; Barlow, D. J.; Hylands, P. J. In silico search for multi-target anti-inflammatories in Chinese herbs and formulas Bioorg. Med. Chem. 2010, 18, 2204-2218
31. Gu, J.; Zhang, H.; Chen, L.; Xu, S.; Yuan, G.; Xu, X. Drug-target network and polypharmacology studies of a Traditional Chinese Medicine for type II diabetes mellitus Comput. Biol. Chem. 2011, 35, 293-297
32. Harvey, A. L.; Clark, R. L.; Mackay, S. P.; Johnston, B. F. Current strategies for drug discovery through natural products Expert Opin. Drug Discov. 2010, 5, 559-568
33. Schuster, D.; Wolber, G. Identification of Bioactive Natural Products by Pharmacophore-Based Virtual Screening Curr. Pharm. Des. 2010, 16, 1666-1681
34. Tou, W. I.; Chen, C.Y.-C. In Silico Investigation of Potential Src Kinase Ligands from Traditional Chinese Medicine. PLoS One 2012, 7.
35. Li, W. L.; Zheng, H. C.; Bukuru, J.; De Kimpe, N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus J. Ethnopharmacol. 2004, 92, 1-21
36. Herrick, T. M.; Million, R. P. Tapping the potential of fixed-dose combinations Nat. Rev. Drug Discovery 2007, 6, 513-514
37. Zhu, F.; Shi, Z.; Qin, C.; Tao, L.; Liu, X.; Xu, F.; Zhang, L.; Song, Y.; Liu, X.; Zhang, J.; Han, B.; Zhang, P.; Chen, Y. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery Nucleic Acids Res. 2012, 40, D1128-D1136
38. Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs, drug actions and drug targets Nucleic Acids Res. 2008, 36, D901-D906
39. Kanehisa, M.; Goto, S.; Sato, Y.; Furumichi, M.; Tanabe, M. KEGG for integration and interpretation of large-scale molecular data sets Nucleic Acids Res. 2012, 40, D109-D114
40. Moller, D. E. New drug targets for type 2 diabetes and the metabolic syndrome Nature 2001, 414, 821-827
41. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242
42. Qiao, X. B.; Hou, T. J.; Zhang, W.; Guo, S. L.; Xu, S. J. A 3D structure database of components from Chinese traditional medicinal herbs J. Chem. Inf. Comput. Sci. 2002, 42, 481-489
43. Shen, M.; Tian, S.; Li, Y.; Li, Q.; Xu, X.; Wang, J.; Hou, T. Drug-likeness analysis of traditional Chinese medicines: 1. property distributions of drug-like compounds, non-drug-like compounds and natural compounds from traditional Chinese medicines J. Cheminform. 2012, 4, 1-13
44. Tian, S.; Li, Y.; Wang, J.; Xu, X.; Xu, L.; Wang, X.; Chen, L.; Hou, T. Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines J. Cheminform. 2013, 5, 1-14
45. Tian, S.; Wang, J.; Li, Y.; Xu, X.; Hou, T. Drug-likeness Analysis of Traditional Chinese Medicines: Prediction of Drug-likeness Using Machine Learning Approaches Mol. Pharm. 2012, 9, 2875-86
46. Chen, C.Y.-C. TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico. PloS One 2011, 6.
47. Discovery Studio 3.1 Guide; Accelrys Inc., San Diego, 2012; http://www.accelrys.com.
48. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R. N.; Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities Nucleic Acids Res. 2007, 35, D198-D201
49. Krueger, D. M.; Evers, A. Comparison of Structure- and Ligand-Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors Chemmedchem 2010, 5, 148-158
50. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196
51. Schrödinger, version 9.0; Schrödinger, LLC, New York, 2009; http://www.schrodinger.com.
52. Kaminski, G. A.; Friesner, R. A.; Tirado-Rives, J.; Jorgensen, W. L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides J. Phys. Chem. B 2001, 105, 6474-6487
53. Sutter, J.; Li, J.; Maynard, A. J.; Goupil, A.; Luu, T.; Nadassy, K. New Features that Improve the Pharmacophore Tools from Accelrys Curr. Comput.-Aided Drug Des. 2011, 7, 173-180
54. Rogers, D.; Hopfinger, A. J. Application of genetic function approximation to quantitative structure-activity-relationships and quantitative structure-property relationships J. Chem. Inf. Comput. Sci. 1994, 34, 854-866
55. Meslamani, J.; Li, J.; Sutter, J.; Stevens, A.; Bertrand, H.-O.; Rognan, D. Protein-Ligand-Based Pharmacophores: Generation and Utility Assessment in Computational Ligand Profiling J. Chem. Inf. Model. 2012, 52, 943-955
56. Chen, L.; Li, Y.; Zhao, Q.; Peng, H.; Hou, T. ADME Evaluation in Drug Discovery. 10. Predictions of P-Glycoprotein Inhibitors Using Recursive Partitioning and Naive Bayesian Classification Techniques Mol. Pharm. 2011, 8, 889-900
57. Wang, S.; Li, Y.; Wang, J.; Chen, L.; Zhang, L.; Yu, H.; Hou, T. ADMET Evaluation in Drug Discovery. 12. Development of Binary Classification Models for Prediction of hERG Potassium Channel Blockage Mol. Pharm. 2012, 9, 996-1010
58. Breitkreutz, B. J.; Stark, C.; Tyers, M. Osprey: a network visualization system Genome Biol. 2003, 10.1186/gb-2003-4-3-r22
59. Cheng, T.; Li, X.; Li, Y.; Liu, Z.; Wang, R. Comparative Assessment of Scoring Functions on a Diverse Test Set J. Chem. Inf. Model. 2009, 49, 1079-1093
60. Cross, J. B.; Thompson, D. C.; Rai, B. K.; Baber, J. C.; Fan, K. Y.; Hu, Y.; Humblet, C. Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy J. Chem. Inf. Model. 2009, 49, 1455-1474
61. Bemis, G. W.; Murcko, M. A. The properties of known drugs 0.1. Molecular frameworks J. Med. Chem. 1996, 39, 2887-2893
62. Yang, L.; Wang, K.; Chen, J.; Jegga, A. G.; Luo, H.; Shi, L.; Wan, C.; Guo, X.; Qin, S.; He, G.; Feng, G.; He, L. Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome-Clozapine-Induced Agranulocytosis as a Case Study. PLoS Comput. Biol. 2011, 7.
63. Durant, J. L.; Leland, B. A.; Henry, D. R.; Nourse, J. G. Reoptimization of MDL keys for use in drug discovery J. Chem. Inf. Comput. Sci. 2002, 42, 1273-1280
64. Matsuda, H.; Shimoda, H.; Morikawa, T.; Yoshikawa, M. Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): Structure-requirement of hydroxyanthraquinones for estrogenic activity Bioorg. Med. Chem. Lett. 2001, 11, 1839-1842
65. Lee, D. Y.; Kim, D. H.; Lee, H. J.; Lee, Y.; Ryu, K. H.; Jung, B.-I.; Song, Y. S.; Ryu, J.-H. New estrogenic compounds isolated from Broussonetia kazinoki Bioorg. Med. Chem. Lett. 2010, 20, 3764-3767
66. Roelens, F.; Heldring, N.; Dhooge, W.; Bengtsson, M.; Comhaire, F.; Gustafsson, J.-A.; Treuter, E.; De Keukeleire, D. Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alpha and beta J. Med. Chem. 2006, 49, 7357-7365
67. Zhao, L. Q.; Brinton, R. D. Structure-based virtual screening for plant-based ER beta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases J. Med. Chem. 2005, 48, 3463-3466
68. Lyons, M. M.; Yu, C. W.; Toma, R. B.; Cho, S. Y.; Reiboldt, W.; Lee, J.; Van Breemen, R. B. Resveratrol in raw and baked blueberries and bilberries J. Agric. Food Chem. 2003, 51, 5867-5870
69. Ferreira, C. V.; Justo, G. Z.; Souza, A. C. S.; Queiroz, K. C. S.; Zambuzzi, W. F.; Aoyama, H.; Peppelenbosch, M. P. Natural compounds as a source of protein tyrosine phosphatase inhibitors: Application to the rational design of small-molecule derivatives Biochimie 2006, 88, 1859-1873
70. Wang, F.-R.; Yang, X.-W.; Zhang, Y.; Liu, J.-X.; Yang, X.-B.; Liu, Y.; Shi, R.-B. Three new isoflavone glycosides from Tongmai granules J. Asian Nat. Prod. Res. 2011, 13, 319-329
71. Ha, D. T.; Tran Minh, N.; Lee, I.; Lee, Y. M.; Kim, J. S.; Jung, H.; Lee, S.; Na, M.; Bae, K. Inhibitors of Aldose Reductase and Formation of Advanced Glycation End-Products in Moutan Cortex (Paeonia suffruticosa) J. Nat. Prod. 2009, 72, 1465-1470
72. Matsuda, H.; Morikawa, T.; Toguchida, I.; Yoshikawa, M. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity Chem. Pharm. Bull. 2002, 50, 788-795
73. Srivastava, S. K.; Ansari, N. H. Prevention of sugar-induced cataractogenesis in rats by butylated hydroxytoluene Diabetes 1988, 37, 1505-1508
74. Wolff, S. P.; Crabbe, M. J. C. Low apparent aldose reductase-activity produced by monosaccharide autoxidation Biochem. J. 1985, 226, 625-630
75. Collier, A.; Wilson, R.; Bradley, H.; Thomson, J. A.; Small, M. Free-radical activity in type-2 diabetes Diabetic Med. 1990, 7, 27-30
76. Sato, Y.; Hotta, N.; Sakamoto, N.; Matsuoka, S.; Ohishi, N.; Yagi, K. Lipid peroxide level in plasma of diabetic-patients Biochem. Med. 1979, 21, 104-107
77. Kannel, W. B.; McGee, D. L. Diabetes and Cardiovascular Risk-Factors-Framingham Study Circulation 1979, 59, 8-13
78. Greene, D. A. Acute and chronic complications of diabetes-mellitus in older patients Am. J. Med. 1986, 80, 39-53
79. Mohora, M.; Virgolici, B.; Paveliu, F.; Lixandru, D.; Muscurel, C.; Greabu, M. Free radical activity in obese patients with type 2 diabetes mellitus Rom. J. Intern. Med. 2006, 44, 69-78
80. Nishimura, C.; Kuriyama, K. Alteration of lipid peroxide and endogenous antioxidant contents in retina of streptozotocin-induced diabetic rats-effect of vitamin-a administration Jpn. J. Pharmacol. 1985, 37, 365-372
81. Paller, M. S.; Hoidal, J. R.; Ferris, T. F. Oxygen free-radicals in ischemic acute-renal-failure in the rat J. Clin. Invest. 1984, 74, 1156-1164
82. Funke, I.; Melzig, M. F. Effect of different phenolic compounds on alpha-amylase activity: screening by microplate-reader based kinetic assay Pharmazie 2005, 60, 796-797
83. He, Z. D.; Lau, K. M.; But, P. P. H.; Jiang, R. W.; Dong, H.; Ma, S. C.; Fung, K. P.; Ye, W. C.; Sun, H. D. Antioxidative glycosides from the leaves of Ligustrum robustum J. Nat. Prod. 2003, 66, 851-854
84. Jang, D. S.; Lee, Y. M.; Jeong, I. H.; Kim, J. S. Constituents of the Flowers of Platycodon grandiflorum with Inhibitory Activity on Advanced Glycation End Products and Rat Lens Aldose Reductase In Vitro Arch. Pharmacal Res. 2010, 33, 875-880
85. Wang, N.; Yang, X.-W. Two new flavonoid glycosides from the whole herbs of Hyssopus officinalis J. Asian Nat. Prod. Res. 2010, 12, 1044-1050
86. Xie, H. H.; Wang, T.; Matsuda, H.; Morikawa, T.; Yoshikawa, M.; Tani, T. Bioactive constituents from Chinese natural medicines. XV.(1))-Inhibitory effect on aldose reductase and structures of saussureosides A and B from Saussurea medusa Chem. Pharm. Bull. 2005, 53, 1416-1422
87. Fang, H.; Tong, W. D.; Shi, L. M.; Blair, R.; Perkins, R.; Branham, W.; Hass, B. S.; Xie, Q.; Dial, S. L.; Moland, C. L.; Sheehan, D. M. Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens Chem. Res. Toxicol. 2001, 14, 280-294
88. Dong, Y.; Shi, H.; Yang, H.; Peng, Y.; Wang, M.; Li, X. Antioxidant Phenolic Compounds from the Stems of Entada phaseoloides Chem. Biodiv. 2012, 9, 68-79
89. Khairullina, V. R.; Gerchikov, A. Y.; Denisova, S. B. Comparative study of the antioxidant properties of selected flavonols and flavanones Kinet. Catal. 2010, 51, 219-224
90. Kong, D.; Zhang, Y.; Yamori, T.; Duan, H.; Jin, M. Inhibitory Activity of Flavonoids against Class I Phosphatidylinositol 3-Kinase Isoforms Molecules 2011, 16, 5159-5167
91. Mueller, M.; Lukas, B.; Novak, J.; Simoncini, T.; Genazzani, A. R.; Jungbauert, A. Oregano: A Source for Peroxisome Proliferator-Activated Receptor gamma Antagonists J. Agric. Food Chem. 2008, 56, 11621-11630
92. Mei, R.-Q.; Lu, Q.; Hu, Y.-F.; Liu, H.-Y.; Bao, F.-K.; Zhang, Y.; Cheng, Y.-X. Three new polyyne (= polyacetylene) glucosides from the edible roots of Codonopsis cordifolioidea Helv. Chim. Acta 2008, 91, 90-96
93. Ilango, K.; Chitra, V.; Kanimozhi, P.; Balaji, G. Antidiabetic, antioxidant and antibacterial activities of leaf extracts of Adhatoda zeylanica. Medic (Acanthaceae) J. Pharm. Sci. Res. 2009, 1, 67-73